Loading clinical trials...
Loading clinical trials...
A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy
Conditions
Interventions
Mazindol
Locations
22
United States
Sleep Disorders Center of Alabama
Birmingham, Alabama, United States
Stanford Sleep Medicine Center
Redwood City, California, United States
Pacific Research Network
San Diego, California, United States
St. Francis Sleep Allergy and Lung Institute
Clearwater, Florida, United States
Sleep Medicine Specialists of South Florida
Miami, Florida, United States
Ivetmar Medical Group
Miami, Florida, United States
Start Date
October 26, 2021
Primary Completion Date
January 19, 2023
Completion Date
January 19, 2023
Last Updated
March 13, 2023
NCT07363720
NCT05816382
NCT06952699
NCT04806620
NCT06809803
NCT06457945
Lead Sponsor
NLS Pharmaceutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions